Relmada Therapeutics Inc. Seeks to Amend Their Complaint against Laidlaw & Company

Laidlaw & Company is an investment banking and brokerage firm. The company has been offering advice on alternative investments and wealth management to public firms, private institutions, and high net worth investors in the United States and the United Kingdom. Matthew D. Eitner heads the company, and James Ahern is the Managing Partner and Head of Capital Markets. Headquartered in New York, the company has over 150 employees who run its operations under FCA authorization and FINRA registration.

Laidlaw offers banking services, which include capital raising, financing the acquisitions, AIM-listed transactions in UK markets, U.S. trading markets, initial public offerings, and arranging the national exchange listing. Additionally, the company gives advice on the balance sheet optimizations, acquisitions and mergers, stock purchasing, and strategic alliance among others. Apart from the investment banking services, the company also gives wealth management services with interests in portfolio management, investment advisory services, and financial planning.

Relmada Therapeutics Inc. announced they had filed a motion to amend its complaints against Laidlaw & Company in January 2016. This is after they filed a lawsuit against the Laidlaw and its principals Matthew Eitner and James Ahern for the dissemination of false and misleading proxy materials. The amended complaint involves an additional legal claim of Laidlaw’s breach of the confidentiality rule that it owed Relmada while serving as the Relmada’s investment banker. It also sought compensations on the costs incurred responding to the December 4 press release and prevented from any future harm by Laidlaw & Company.

Relmada Therapeutics is a pharmaceutical company that develops proven products that aid in the medical treatment. The company emailed the information about Laidlaw’s action to their stockholders as a way of assuring them of their commitment to protecting their rights. Relmada stock that was previously trading at $4.03 per share has drastically dropped to $1.65 following the Laidlaw’s press release.

Leave a Reply

Your email address will not be published. Required fields are marked *